Holen Sie sich die Stockscreener-App
12.42
4.19%
0.50
Handel nachbörslich:
12.42
Schlusskurs vom Vortag:
$11.92
Offen:
$11.99
24-Stunden-Volumen:
645.68K
Relative Volume:
2.33
Marktkapitalisierung:
$621.02M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-13.50
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
+11.09%
1M Leistung:
+9.91%
6M Leistung:
+31.01%
1J Leistung:
+50.00%
1-Tages-Spanne:
$11.92
$12.68
1-Wochen-Bereich:
$11.04
$12.68
52-Wochen-Spanne:
$7.88
$12.68
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
12.42 | 570.02M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - Nasdaq
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com UK
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
What institutional flow reveals about Theravance Biopharma Inc.Trade Safety Matrix for Conservative Traders - Newser
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Theravance Bio: Q2 Earnings Snapshot - San Francisco Chronicle
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Is Theravance Biopharma Inc. still worth holding after the dipFree Smart Money Tracking Signal Generator - Newser
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedTrend Confirmation Scanner with Entry Focus - Newser
Signal strength of Theravance Biopharma Inc. stock in tech scannersRisk Aware Trading Ideas with Alert Levels - Newser
Real time pattern detection on Theravance Biopharma Inc. stockIntraday Signal Forecast for Fast Traders - Newser
Price momentum metrics for Theravance Biopharma Inc. explainedFree News Based Entry Opportunity Alerts - Newser
Tools to monitor Theravance Biopharma Inc. recovery probabilitySwing Watchlist With Tight Stop Placement - Newser
Using data models to predict Theravance Biopharma Inc. stock movementSmart Stock Forecast Using AI Algorithms - Newser
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Moving Average Trends for Theravance Biopharma Inc. Stock: What They IndicateTechnical Entry Plan with Risk Minimization - Newser
Theravance Biopharma Inc expected to post earnings of 67 cents a shareEarnings Preview - TradingView
Theravance Biopharma Inc. Stock Performance After Earnings: Historical InsightsFree Conservative Entry for High Return Setup - Newser
What makes Theravance Biopharma Inc. stock price move sharplyHigh Conviction Screener with Trend Matching - Newser
How Theravance Biopharma Inc. stock performs during market volatilitySmart Trade Forecast Based on Neural Logic - Newser
Technical Charts Suggest Momentum Shift in Theravance Biopharma Inc.Chart Driven Price Action Analysis - beatles.ru
What’s the recovery path for long term holders of Theravance Biopharma Inc.Free ROI Boosting Trade Opportunity Calendar - Newser
What is the dividend policy of Theravance Biopharma Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Theravance Biopharma Inc. stock overvalued or undervaluedInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Theravance Biopharma Inc.Maximize gains with timely market signals - Jammu Links News
What are the technical indicators suggesting about Theravance Biopharma Inc.High-velocity gains - Jammu Links News
How volatile is Theravance Biopharma Inc. stock compared to the marketBreakthrough profits - Jammu Links News
What analysts say about Theravance Biopharma Inc. stockSuperior returns - Jammu Links News
Should I hold or sell Theravance Biopharma Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What is Theravance Biopharma Inc. company’s growth strategyMaximize your gains with professional insights - Jammu Links News
What drives Theravance Biopharma Inc. stock priceAchieve rapid returns with smart investment plans - Jammu Links News
How strong is Theravance Biopharma Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Why is Theravance Biopharma Inc. stock attracting strong analyst attentionHigh-profit capital plays - Jammu Links News
What earnings revisions data tells us about Theravance Biopharma Inc.AI Generated Momentum Stock Forecast Guide - Newser
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):